Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 4/20 | 0.50 |
| ▸ | CETP | P11597 | 3/20 | 0.48 |
| ▸ | GALR1 | P47211 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | KIF11 | P52732 | 2/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.40 |
| ▸ | RXRA | P19793 | 1/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL254534 | 1.00 | GPR3 (0.50) | GPR3CETPGALR1SYKKIF11 | |
| SCHEMBL27383227 | 0.89 | SLC22A12 (0.43) | GPR3CETPGALR1CHRM2CHRM1 | |
| SCHEMBL3147185 | 0.85 | GPR3 (0.50) | GPR3CETPGALR1KIF11CHRM2 | |
| SCHEMBL246293 | 0.84 | MAOB (0.40) | GPR3CETPNFE2L2 | |
| SCHEMBL16144539 | 0.83 | MAOB (0.42) | CETPNFE2L2 | |
| SCHEMBL13144294 | 0.81 | CETP (0.52) | CETP | |
| SCHEMBL28123515 | 0.80 | NPC1 (0.47) | GPR3CETPHSD11B1 | |
| SCHEMBL10294030 | 0.80 | NFE2L2 (0.43) | KIF11NFE2L2 | |
| SCHEMBL7940650 | 0.80 | NFE2L2 (0.39) | NFE2L2 | |
| SCHEMBL2094855 | 0.79 | GPR3 (0.45) | GPR3CETPGALR1SYKKIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024196936-A2 | LOCALIZED HIGH CONCENTRATION ELECTROLYTE AND LITHIUM-ION BATTERY COMPRISING THE SAME | SILA NANOTECHNOLOGIES, INC. (US) | 2024-09-26 | — | — | WO | claimed |
| EP-4703359-A1 | IMIDAZOPYRIDINE OR IMIDAZOPYRAZINE COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | Shanghai Simr Biotechnology Co., Ltd. (CN) | 2026-03-04 | — | — | EP | disclosed |
| WO-2024196936-A2 | LOCALIZED HIGH CONCENTRATION ELECTROLYTE AND LITHIUM-ION BATTERY COMPRISING THE SAME | SILA NANOTECHNOLOGIES, INC. (US) | 2024-09-26 | — | — | WO | disclosed |
| CN-118515663-A | Imidazopyridine or imidazopyrazine compounds, preparation method, pharmaceutical composition and application thereof | 上海赛默罗生物科技有限公司 | 2024-08-20 | — | — | CN | disclosed |
| CN-117402143-A | EGFR inhibitor and preparation and application thereof | 上海翰森生物医药科技有限公司 | 2024-01-16 | — | — | CN | disclosed |
| CN-117069700-A | EGFR inhibitor and preparation and application thereof | 上海翰森生物医药科技有限公司 | 2023-11-17 | — | — | CN | disclosed |
| CN-111170991-B | Antiproliferative compounds and methods of synthesis thereof | 细胞基因公司 | 2023-10-31 | — | — | CN | disclosed |
| CN-111187221-B | EGFR inhibitor and preparation and application thereof | 上海翰森生物医药科技有限公司 | 2023-09-26 | — | — | CN | disclosed |
| CN-111171000-B | EGFR inhibitor and preparation and application thereof | 上海翰森生物医药科技有限公司 | 2023-09-01 | — | — | CN | disclosed |
| CN-112955436-B | 6-oxo-1, 6-dihydropyridazine derivatives, preparation method and application thereof in medicines | 福建盛迪医药有限公司 | 2023-08-11 | — | — | CN | disclosed |
| CN-111170999-B | EGFR inhibitor and preparation and application thereof | 上海翰森生物医药科技有限公司 | 2023-06-30 | — | — | CN | disclosed |
| US-20220073471-A1 | 6-OXO-1,6-DIHYDROPYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | JIANGSU HENGRUI MEDICINE CO (CN) | 2022-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220073471-A1 | 6-OXO-1,6-DIHYDROPYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | CACNA1D, CACNA1F, CACNA1B | GPR3 2327/4885CETP 2445/4885GALR1 2361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.